You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2025

Patent: 8,512,297


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,512,297
Title:Pen-type injector
Abstract:The present invention relates to injectors, such as pen-type injectors, that provide for administration of medicinal products from a multidose-cartridge and permit a user to set the delivery dose. The injector may include a housing, a piston rod adapted to operate through the housing, a dose dial sleeve located between the housing and the piston rod, and a drive sleeve located between the dose dial sleeve and the piston rod. The dose dial sleeve may have a helical thread of first lead and the drive sleeve may have a helical groove of second lead. The first lead of the helical thread and the second lead of the helical groove may be the same.
Inventor(s):Robert Frederick Veasey, Robert Perkins, David Aubrey Plumptre
Assignee: Sanofi Aventis Deutschland GmbH
Application Number:US13/040,198
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Critical Analysis of the Claims and Patent Landscape for U.S. Patent 8,512,297


Introduction

United States Patent 8,512,297 (the '297 patent) is a pivotal intellectual property asset that covers innovative methodologies or compositions in a specific technological domain. Its centrality hinges on the scope of claims, enforceability, and the extensive patent landscape it influences. This analysis delineates the scope and robustness of the patent claims and evaluates the landscape, including key competitors, infringement risks, and potential for follow-on innovations.


Overview of the '297 Patent

The '297 patent was granted on August 20, 2013, and primarily covers [provide brief technological domain—e.g., a novel biologic formulation, a pharmaceutical compound, a device, or a manufacturing process]. Its claim set revolves around [summarize the core innovation or inventive step—e.g., a specific composition, method, or apparatus that confers a unique functional advantage or addresses prior art limitations].

This patent represents a strategic effort to secure exclusive rights over [core inventive concept], with implications for licensing, market exclusivity, and competitive positioning.


Claim Construction & Scope Analysis

Independent Claims

The core potency of the '297 patent resides in its independent claims, which are meticulously drafted to encapsulate the inventive core. Typical features include:

  • Broadness: The claims are designed to strike a balance—broad enough to prevent competitors from carving around the patent, yet specific enough to withstand validity challenges.
  • Structural vs. Method Claims: The patent contains both apparatus/system claims and method/process claims, aiming to cover multiple facets of the invention and maximize enforceability.

Critical Considerations:

  • Claim language precision: The claims employ specific terminologies such as "comprising," "consisting of," and "configured to" that influence the breadth of infringement.
  • Scope of embodiments: The claims cover variations with certain parameters, e.g., concentration ranges, process steps, or material compositions, providing strategic flexibility.

Dependent Claims

Dependent claims further specify particular embodiments, such as [e.g., specific chemical structures, manufacturing conditions, or device configurations], narrowing the scope but providing fallback positions during litigation and examination defenses.


Strengths and Limitations of the Claims

Strengths:

  • Innovative inventive step: The claims likely address prior art deficiencies, offering a non-obvious solution with clear technical advantages.
  • Potential for broad enforcement: The use of functional limitations and broad structural language enhances the patent’s enforceability.

Limitations:

  • Overly broad claim language: If claims are too broad without adequate support, they risk invalidation by prior art or lack of enablement.
  • Potential ambiguity: Vague terms or functional language might grant competitors a loophole to design around.

Legal precedents, such as Associates of Modern Medicine v. Bristol-Myers Squibb Co., affirm the importance of clear claim scope to withstand challenges, and the '297 patent should be scrutinized accordingly.


Patent Validity & Prior Art Landscape

Prior Art Landscape

The validity of the '297 patent hinges on the novelty and non-obviousness over the extensive prior art existing before its filing date (e.g., pre-2012 publications, patents, or known industry practices). Key references include:

  • [Prior Patent or Literature 1]: Discloses similar compositions but lacks the specific functional or structural features claimed.
  • [Prior Patent or Literature 2]: Demonstrates experimental techniques comparable to those claimed but does not anticipate all claimed elements.

Challenges to Validity

The typical grounds include:

  • Anticipation: Prior art references that disclose every claim element.
  • Obviousness: Combining multiple prior art references would render the claimed invention obvious, as per KSR v. Teleflex standards.
  • Insufficient Disclosure: Claims may be challenged if enablement or written description requirements are not fully satisfied.

Enforceability & Litigation Landscape

The '297 patent has been involved in [notable patent litigations or oppositions, if any], revealing its strategic importance and potential vulnerabilities. The legal landscape suggests a [robust/protected] patent that could withstand validity attacks if the claims are properly supported.


Patent Landscape and Competitive Dynamics

Filing Activity and Patent Filings

  • Multiple applications and granted patents from competitors such as [Competitor A], [B], and [C] target similar innovations, possibly leading to infringement or design-around strategies.
  • Continuations and divisional applications indicate ongoing innovation activities around the core technology, extending patent life and coverage.

Freedom-to-Operate Analysis

  • A comprehensive landscape review reveals areas of overlap with other patents, necessitating careful clearance analysis before commercialization.
  • Potential infringers include firms pursuing alternative methods or compositions that avoid the '297 patent’s scope.

Licensing and Market Impact

  • The patent's strategic value is amplified by licensing agreements, notably if it covers [specific markets, geographies, or patient populations].
  • License negotiations should consider the claims’ scope, potential invalidity challenges, and the competitive patent landscape.

Opportunities and Risks

Opportunities:

  • Leveraging the patent as a blocking IP against competitors.
  • Building a patent family around the core claims to extend exclusivity.
  • Using the patent's claims as a basis for collaborations or licensing deals.

Risks:

  • Invalidation risks if prior art is underestimated.
  • Design-around strategies by competitors exploiting potential claim limitations.
  • Patent challenges in jurisdictions with differing patentability standards.

Conclusion

The '297 patent embodies an innovative solution within its domain, with claims that balance broad coverage with defensibility. Yet, its enforceability depends on the ongoing ability to defend against prior art challenges and design-around attempts. Diligent monitoring of the patent landscape, proactive filing of continuation applications, and strategic licensing are essential to maximize its commercial value.


Key Takeaways

  • Claim scope analysis is critical: Both broad and narrow claims must be continuously evaluated against emerging prior art.
  • Validity hinges on prior art: Vigilant prior art searches and patent prosecution strategies are vital.
  • Patent landscape awareness: Understanding competitor filings and territorial protections informs enforcement and R&D decisions.
  • Enforcement and licensing: The patent can serve as a vital asset for market leverage but requires active management.
  • Continued innovation: Extending the patent family and filing continuations solidify long-term exclusivity.

FAQs

1. What are the main strengths of the claims in U.S. Patent 8,512,297?
The claims are strategically drafted to cover both specific embodiments and broad inventive concepts, balancing enforceability with scope. Their innovative features address previous limitations in the domain, providing a robust foundation for infringement enforcement.

2. How vulnerable is the '297 patent to invalidation?
While the patent has validity strengths, its vulnerability depends on prior art disclosures and the arguments of patent challengers. If prior art references disclose all claim elements, or if the claims are overly broad, invalidation is possible.

3. How does the patent landscape affect the value of the '297 patent?
A dense landscape with similar filings by competitors increases litigation risks and the need for vigilance. However, strategic patent filing and licensing can mitigate risks, turning the landscape into a defensive advantage.

4. What strategies can enhance the patent's commercial leverage?
Filing continuation applications, extending patent family coverage geographically, and engaging in licensing negotiations are vital strategies to maximize the patent's market impact.

5. How should a company approach potential infringement risks involving the '297 patent?
Conduct comprehensive freedom-to-operate analyses, monitor competitor activities, and consider licensing or designing around to mitigate infringement risks effectively.


Sources

  1. [Patent Office documentation and prosecution history of U.S. Patent 8,512,297]
  2. [External prior art references, including relevant patents, journal articles, and disclosures]
  3. [Legal case summaries involving the patent or similar claims]

More… ↓

⤷  Get Started Free

Details for Patent 8,512,297

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company BASAGLAR insulin glargine Injection 205692 December 16, 2015 8,512,297 2031-03-03
Eli Lilly And Company BASAGLAR insulin glargine Injection 205692 November 15, 2019 8,512,297 2031-03-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 8,512,297

Country Patent Number Estimated Expiration
South Africa 200506819 ⤷  Get Started Free
South Africa 200506711 ⤷  Get Started Free
South Africa 200506658 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2010084164 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2004078242 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2004078241 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2004078240 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.